Kaneka Medical America Expands Neurovascular Portfolio with U.S. Launch of WaveSelect 1014 Guidewire
Published: 15 Jan 2026
Author: Precedence Research
Kaneka Medical America LLC, an offshoring subsidiary of Japan-based Kaneka Corporation, has announced the introduction of the WaveSelecttm 1014 guidewire in the U.S. market. This is an important advancement in the strategy of the company in the field of neurovascular devices. Its introduction is being done through an exclusive distribution agreement with Enlight Medical Ltd., which gives Kaneka the exclusive right to commercialize the next-generation guidewire technology. The action affirms the long-term strategy of Kaneka to seek to promote minimally invasive approaches to complex cases involving the neurovascular. This provides further access to innovative interventional solutions for both physicians and patients.
The WaveSelecttm 1014 guidewire is developed to solve enduring clinical issues in neurovascular surgeries, especially that of using complex and delicate anatomy. The guidewire was created in Japan, and it uses proprietary polymer metal matrix technology, which sets it apart from other designs. This developed type of construction is designed to provide optimal balance between flexibility, control, and support, resulting in better microcatheter deliverability. The introduction of this model allows Kaneka to be in a better position to serve clinicians wanting reliable access solutions in a broad application involving neurovascular access.
The launch of WaveSelect can be seen as the role of Kaneka Medical America to reinforce and diversify its neurovascular portfolio to adapt to the changing clinical requirements. Neurovascular disease is one of the major causes of disability and death across the world. The need to establish accurate and reliable access technologies is ever-increasing with the sophistication of the procedures. In collaboration with Enlight Medical, Kaneka is taking the opportunity of utilizing complementary expertise. This enables them to introduce the advanced guidewire solutions in the U.S. market without losing focus on performance, safety, and efficiency of procedures.
Executive’s Statement
Ken Toda, President of Kaneka Medical America, commented on the announcement, stating, “The launch of WaveSelect significantly strengthens our neurovascular portfolio and reinforces our mission to provide physicians with advanced tools that improve patient outcomes. By partnering with Enlight Medical, we are bringing a highly differentiated guidewire technology to the U.S. market, one that reflects our shared commitment to performance, innovation, and long-term clinical value.”